drugset / Trial / NCT04827745
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a research study to find out if a drug called blinatumomab is effective for treating patients with relapsed or refractory (R/R) or measurable residual disease (MRD) CD19-positive mixed phenotypic acute leukemia (MPAL). Measurable Residual Disease (MRD) means that there are a small number of cancer cells remaining after treatment
Timeline
- Start
- 2021-06-11
- Primary completion
- 2025-05-22
- Completion
- 2025-05-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | 28 ug | Intravenous |